posted
holding long here has been frustrating, but, it will pay off..... good news today....
(QUOTE)
2004-07-13 12:41:14
Sinovac Biotech Ltd. Reports 2003 Sales Growth of Over 400% and Expects a Further 300-400% Revenue Increase in 2004
***
Health/Medical Writers / Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac", "the Company") (OTCBB:SNVBF) has recorded 2003 sales growth of more than 400% according to the Company's audited financial statements filed recently with the SEC. In order to view Sinovac's complete latest 20F annual financial statement filing please refer to the SEC website at www.sec.gov, click on "Search for Company Filings", then click on "Companies & Other Filers", then input "Sinovac" in the "Company Name" box, and then click on the most recent filing "Form 20F". Alternatively, contact Sinovac Investor Relations at info@sinovac.com to request a copy of the Sinovac 20F financial report by email or mail. This filing contains many details of Sinovac's financial statements and business plan, including such aspects as principal products, the market for these products, marketing strategy, R & D, and competition. Management of Sinovac are currently projecting sales of more than US $10 million for the current year ending 31st December 2004 - an increase between three and four times the currently reported 2003 sales. Management is also awaiting the imminent final approval of its combined Hepatitis A&B vaccine by the Chinese FDA
(QUOTE--abreviated for laststock--LOL)
[This message has been edited by glassman (edited July 13, 2004).]
Avian Flu --------- Avian Flu - The Chinese government assigned the task of Avian Flu R&D to the Company and the Center for Disease Control of China on the latest Key Science-Technology Project of the National 'Tenth Five-Year-Plan' of China, called "Research and Development of a New Human Influenza Vaccine". The Company 16 finished the research protocol early in 2004 and started working towards a vaccine. The leading world health authority influenza network provided the prototype bird flu virus to vaccine makers around the world.
(QUOTE)
these guys are not just developing a better marketing system they are researching(and getting US gov. funding to do it)
[This message has been edited by glassman (edited July 13, 2004).]
I've held this at various times over the past few months - essentially for a week or two each time. I've made some decent profits, but have (wisely) been afraid to commit to a long-term hold. I can't foresee any reason why this wouldn't be doing much better except for the notion that this is currently a trader's market. So I ask - do you think more investors will be coming on board in the coming months as we near the election? I'd like to hold this long-term...
Posts: 156 | From: Philadelphia, PA, USA | Registered: Jan 2004
| IP: Logged |
posted
i don't know shushan. the markets are being affected by quite a few variables.it's not just the election, it's oil prices and sabatoge fears,the interest rates, not catching Osam Bin Alive Too Long, China cutting growth....yada yadda yaaddddaa.... the low share count on this one makes it vulnerable to market instability--BOTH WAYS i continue to hold because when it flies, it's going to really fly and it will be hard to catch.....
(QUOTE)
---- Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report. 27,091,033 common shares (as at the financial year ended December 31, 2003) --------------------------------------------------------------------------- 34,770,233 common shares (as at May 31, 2004) --------------------------------------------- Indicate by check
(QUOTE)
someone mentioned a forward split(2for1) a little while back to reduce volatility. It seemed to have a negative impact on the PPS, which i didn't understand. i welcome a fwd split, and if they do it i will double my postion again....
posted
hey glass, what's up?! good to see you survived the move. i too am surprised that SNVBF has dropped so far, wasn't expecting it. i sold all mine awhile back not because i didn't like the stock, but when ALMI dipped to .15 i couldn't resist and sold nearly everything i owned to buy all ALMI. if ALMI pops through the summer and SNVBF is still low, will definitely pick some up. need to pick up some CLSI too, was painful selling that because I like the company so much. guess PG is gone for good, eh? what a shame, i really miss her wit and insight
Posts: 1698 | Registered: Mar 2004
| IP: Logged |
posted
hard to say about PG. she may show up when the market gets healthy again. i do seem to recall her saying something about the market going down just before she took a powder.... i have no doubt that she has other interesting projects where her efforts are more wisely spent.. ALMI has come up some for you i see, we might get it back to .27 before the election....
Posts: 36378 | From: USA | Registered: Sep 2003
| IP: Logged |
posted
HOT OFF THE PRESSES (well, the internet then LOL)
2004-07-14 09:45:14
Sinovac Biotech Ltd. Updates on Application to American Stock Exchange
***
Health/Medical Writers / Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac", "the Company") (OTCBB:SNVBF) has filed application to be listed on the American Stock Exchange ("AMEX"). The American Stock Exchange is the second largest trading floor based exchange in the United States. Sinovac currently trades on the NASD Over the Counter Bulletin Board (OTC-BB). The company has taken the necessary steps to meet the requirements to be included on the AMEX. The American Stock Exchange has established certain quantitative and qualitative standards for the initial listing of foreign companies. Sinovac has made application under Standard 3 which requires the following quantitative standards: -0- *T Shareholders' equity $4 million Total market capitalization $50 million Distribution 800 public shareholders and 500,000 shares publicly held OR 400 public shareholders and 1 million shares publicly held OR 400 public shareholders, 500,000 shares publicly held, and average daily trading volume of 2,000 shares for previous 6 months Market value public float $15 million *T Sinovac currently has shareholders' equity of approximately US $10 million. At a $3 share price, the Company has a $105 million market capitalization. As of May 2004, Sinovac had over 4,000 shareholders. Finally, the market value of the freely tradeable public float is currently over $30 million. Thus, Sinovac management believes that it currently meets, and indeed well exceeds the quantitative criteria for listing on the American Stock Exchange.
posted
as i have stated over and over charting is not my strongest point... looking at the 5 month chart, i would hazard a guess that the sellers are (finally) all done..... this may be the most gains on the lowest volumes we have seen.... i know a lot of you that watch bio-techs know how quickly they can runup....... Posts: 36378 | From: USA | Registered: Sep 2003
| IP: Logged |
posted
How long does it usually take to hear whether the AMEX has accepted their application or not?
IP: Logged |
Goonman
unregistered
posted
More good news today btw...
Sinovac Biotech Ltd. Files Drug Registration for International Markets for its Hepatitis A Vaccine Thursday July 22, 8:32 am ET
BEIJING--(BUSINESS WIRE)--July 22, 2004--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (OTCBB:SNVBF - News) announces vaccine registration applications for its Hepatitis A vaccine have been submitted in nine countries: Brazil, Indonesia, Mexico, Malaysia, Pakistan, Philippines, Sri Lanka, Thailand, and Vietnam. Each country's application requirements vary, and the Company is waiting on formal responses from official health authorities in each of these countries.
Sinovac is currently experiencing strong sales growth of its Hepatitis A vaccine, Healive. Management of Sinovac is currently projecting domestic Chinese sales of approximately US $10 million for the current year ending 31st December 2004 - an increase of more than three times 2003 sales. Management expects to receive final approval of its combined Hepatitis A&B vaccine by the Chinese FDA in August, and expects to commence sales of this product by October, 2004.
Sinovac intends to replicate its dramatic Chinese sales growth of Healive in the international marketplace. The company is energetically pursing global market development opportunities and achieving initial marketing strategy goals.
Sinovac is actively developing its international market and collaborating with professional and well-rounded companies in order to accelerate its international marketing strategy, while simultaneously taking its advantage of its state-of-the-art R&D capabilities. To date, Sinovac has selected two experienced marketing and sales companies to assist in marketing its products in international markets.
Innopath International, a Korean company, has enormous international vaccine market experience and a well-organized worldwide sales network. Innopath's management team is assisting Sinovac in developing its international sales. This assistance includes marketing strategy development, registration in some of the targeted countries, and the establishment of distribution channels through Innopath's existing relationships with vaccine distributors in the international market.
Another international sales agent for Sinovac is China National Medicine & Health Products Import/Export Corporation (abbreviated in China as MEHECO). It is one China's largest import/export and domestic trade enterprises in the field of medicines and healthcare products with US$6.3 billion in its import and export business for the past 18 years. MEHECO has a reputation for nurturing diverse relationships with customers from more than one hundred countries and regions in the world.
"These nine countries represent Sinovac's first foreign applications for its affordable world-class vaccines. These vaccine registration applications represent our initial international markets as we make progress towards sales in 32 targeted countries." stated Sinovac's president, Dr. Wei Dong Yin.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and "SARS." Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.
For further information please refer to the Company's filings with the SEC on EDGAR or refer to Sinovac's website at www.sinovac.com.
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Sinovac Biotech Ltd. Updates on Phase I Human Clinical Testing of SARS Vaccine
***
Health/Medical Writers / Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- All 36 Subjects Have Now Been Inoculated with Either SARS Vaccine or Placebo and Are in Good Health Condition Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) announces that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with either SARS vaccine or placebo. The final 12 subjects in the second group of 18 volunteers have received the vaccination, 6 subjects on July 28 and 6 subjects on August 4, 2004. No adverse side-effects have been observed. As previously announced, the first 6 of this second group of 18 volunteers in the SARS vaccine trial were injected on July 15, 2004.
posted
not really new news, but a good op to put this back on top of the list.LOL
getting into the AMEX is pretty big, considering how fast this company has moved forward....i don't expect an immediate jump in PPS cuz of it, but it should generate a lot of new interest....institutional investors would be a good thing.....
2004-08-11 06:35:03
Sinovac Biotech Updates on its Application to the American Stock Exchange 'AMEX' and Announces the Appointment of New Additions to the Board of Directors
***
Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac") ("the Company") (OTCBB:SNVBF) updates on the forthcoming listing on the American Stock Exchange (AMEX). Sinovac's application for listing on AMEX has progressed to the point that management believes the Company will be listed in August or early September of 2004. Once accepted on the American Stock Exchange, Sinovac will again demonstrate its leadership as one of China's most modern, publicly traded biotechnology companies. Sinovac management believes that the Company will derive several benefits from its listing on AMEX. Once listed, Sinovac will become more desirable to institutional investors, receive broader investor awareness, and improved share price stability and liquidity. In continuing efforts to ensure good corporate governance, Sinovac announces the appointment of Mr. Simon J. Anderson and Mr. Hao You to the Company's Board of Directors. In addition, Sinovac has appointed a new audit committee, comprised of Dr. K.K. Ong, Mr. Simon J. Anderson and Mr. Hao You in order to ensure that the audit committee is comprised entirely of expert, impartial directors as required by AMEX corporate governance standards. Mr. Simon J. Anderson brings excellent credentials to Sinovac.
posted
some buying interest here today--- anticipation of going to the AMEX i assume... i believe this is going to do very well IF it gets on the AMEX......
Posts: 36378 | From: USA | Registered: Sep 2003
| IP: Logged |
bishopsbell
unregistered
posted
Is there someway to email you about for a opinion on a stock?
IP: Logged |
posted
OK, this PR is projecting future(2+ years) REVENUES of 10 million$/year on just one vaccine..... that's why i am in this one for the duration.... notice they are going to need to raise 5 million$ soon....
2004-09-16 08:05:04
Sinovac Biotech Ltd. Updates on the Progress of its Proprietary Split Flu 'Influenza' Vaccine
***
Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) announced today its progress on government approval, production facility, and marketing of its proprietary split flu (influenza) vaccine. Sinovac's flu vaccine completed clinical trials in April 2004 and a New Drug Application has been filed with the SFDA (Chinese FDA). Approval of Sinovac's flu vaccine is expected in 2005 upon completion of the flu vaccine production line. Since demand for a safe and effective flu vaccine in China greatly outstrips supply, sales are expected to escalate rapidly. Furthermore, since individuals require vaccination against the flu on an annual basis, demand will remain high every year. The Company plans to produce 500,000 doses of vaccine in 2005 and then increase to 2 million doses for the 2005-2006 flu season. After these initial production levels, it is Sinovac's intention to expand production capacity to as much 20 million doses to meet the escalating demand of the Chinese population. This increased capacity will be contingent on securing appropriate expansion financing. The sales price of the split flu vaccine is anticipated to be around US $5 per dose. Sinovac's flu production line will be launched at a new manufacturing facility next to Sinovac's existing Beijing headquarters. The 2600 square meter facility is being built to global Good Manufacturing Practice (GMP) standards
[
[This message has been edited by glassman (edited September 16, 2004).]
posted
last year, when the market was gaining steam, and bio-techs were hot, a conference like this was a slamdunk for 10%+ on the day.... i haven't seen evidence that this kind of pattern will hold true right now, but......
2004-09-21 08:17:04
Sinovac-The World's Only Company in Human Clinical Trials for a SARS Vaccine-Is to Present at the Prestigious UBS Global Life Sciences Conference on Thursday Sept. 30 in New York City
***
Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) has been invited by Union Bank of Switzerland ("UBS") to present at the UBS Global Life Sciences Conference being held at The Grand Hyatt in New York City, September 27-30, 2004. Sinovac, currently the first and only company to have commenced clinical trials for a vaccine to prevent SARS, will present an update on its SARS clinical trials, its Hepatitis A and Hepatitis A&B vaccines, and its vaccines for Infuenza and Avian flu under development. Sinovac's 25-minute presentation on Thursday September 30 at 2:30 p.m. will be followed immediately by a 25-minute breakout session. Management of Sinovac would like to invite shareholders, investors, and all interested parties to this presentation.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
